Our Priority: Ensure Patient Access to PSA Testing
News & Updates
House VA Committee Holds Hearing on H.R. 6092
On September 10, the House Committee on Veteran’s Affairs held a hearing on a number of bills, including the Veteran’s Prostate Cancer Treatment and Research Act (H.R. 6092). The AUA submitted a statement on the record in support of this important bill.
Read the statement. [pdf]
Why the Issue Matters
Prostate cancer is the second-leading cause of cancer deaths for men in the U.S. About 1 in 9 men will be diagnosed with prostate cancer in their lifetime. This year, nearly 191,000 men will be diagnosed with prostate cancer. Also, prostate cancer is the leading cancer diagnosis in the Veterans Health Administration, and currently, over 488,000 veterans are receiving care for prostate cancer. Despite this, patient access to screening for prostate cancer has been threatened by state and federal agencies as well as public and private payors.
The AUA is committed to preserving patients' access to appropriate prostate cancer testing and is working at both the federal and state levels to educate lawmakers on this important issue.
What the AUA is Doing
H.R. 6092, the Veteran’s Prostate Cancer Treatment and Research Act – introduced by Reps. Neal Dunn, MD (R-FL-02) and Joe Cunningham (D-SC-01) – would:
- Direct the Department of Veterans Affairs to establish a clinical pathway for prostate cancer across the public and private sector;
- Ensure that the Department continues to engage in prostate cancer research; and
- Create a real-time registry to:
- Track patient progress;
- Further develop clinical pathways, and
- Allow access to cutting edge clinical trials
H.R. 5200, PSA Screening for HIM Act – introduced by Reps. Bobby Rush (D-IL-01) and Larry Bucshon, MD (R-IN-08) – would waive cost-sharing, including deductibles, copayments, and coinsurances, for prostate cancer screenings for men who have a family history of prostate cancer or who are African-American.